New pastille and all-in-one vape formats, expanded oil and softgel offerings, and new flower SKUs build on international growth momentum

SMITHS FALLS, ON – September 8, 2026 – Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.

“Expanding our product offering in established markets like Australia is central to our international medical strategy,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “These new formats and formulations reflect the continued strength of our global supply chain and our ability to evolve our existing portfolio while bringing a broader range of high-quality products to international markets.”

New formats, now available

• Pastilles – Canopy Growth’s first pastille format in Australia:
  • Tweed Red 10
  • Tweed Blue 10:10
  • Spectrum Triple Balance 10:10:10
  • Spectrum Dawn 1:10:5

• All-in-one vapes – Canopy Growth’s first AIO vape format in Australia:
  • 7 ACRES Fondant Live Resin AIO Vape 1 mL (Indica)
  • Spectrum Therapeutics Reserve Berea Live Resin AIO Vape 1 mL (Sativa)

Expanded formulations, now available

• Oils – Canopy Growth’s first Australian oils to include CBG and CBN:
  • Spectrum Flow
  • Spectrum Sunset

• Softgels – expanding the range beyond isolate based formulations:
  • Spectrum White 50
  • Spectrum Black 10

Also new to the portfolio

• Flower:
  • Two new SKUs added under the Twd. value range

“Prescribers and patients in Australia are asking for more choice in format and formulation,” said Andrew Bevan, President, Medical, Canopy Growth. “These launches give clinicians more options to tailor treatment approaches, while our new pastille and oil offerings reflect formulation work shaped by insights from our Canadian clinic and provider network.”